The electrochemiluminescence (ECL) bioassay is prominently
carried
out with the involvement of the coreactant. To remove the detrimental
effects of the coreactant on the ECL of luminophores, herein, a promising
ECL immunoassay strategy with biocompatible nanoparticles as the luminophore
is proposed, which involves directly and electrochemically oxidizing
the luminophore methionine-capped Au (Met@Au) nanocrystals (NCs) without
the participation of any coreactant. Met@Au NCs are a kind of n-type
nanoparticles, and they can be electrochemically injected with valence
band (VB) holes around +0.80 and +1.10 V (vs Ag/AgCl). The electrochemically
injected exogenous VB hole can recombine with the endogenous conduction
band electron of Met@Au NCs and eventually bring out two coreactant-free
and near-infrared ECL processes around 0.80 V (ECL-1) and 1.10 V (ECL-2).
The intensity of coreactant-free ECL is primarily determined by the
electrochemical oxidation-induced hole-injection process. ECL-2 is
considerably stronger than ECL-1 and can be exploited for determining
the carcinoembryonic antigen (CEA) in a sandwich immunoassay procedure
with a linear range from 0.1 to 50 pg/mL as well as a limit of detection
of 0.03 pg/mL (S/N = 3).